CTGov Compliance My Organizations

Compliance Rate

Compliance Rate 100.0%

Compliant submissions 1

Incompliant submissions 0

Total trials 1

My Organizations' Clinical Trials

Showing 100 of 279 entries

View as:

Donor Umbilical Cord Blood Natural Killer Cells, Aldesleukin and Umbilical Cord Blood Transplant in Patients With Refractory Hematologic Cancers.

Phase: N/A Priority: Normal

NCT ID: NCT00354172 Org: User:

Start: 02/28/06 End: 08/31/08 Due: 08/31/09

MT2022-01: MSCs for ALD

Phase: N/A Priority: Normal

NCT ID: NCT06030648 Org: User:

Start: 08/28/23 End: 05/01/28 Due: 05/01/29

Probiotic Supplementation During Cytotoxic Chemotherapy for Solid Tumor Malignancies

Phase: N/A Priority: Normal

NCT ID: NCT06772090 Org: User:

Start: 12/25/25 End: 12/31/27 Due: 12/31/28

Study of FT516 for the Treatment of COVID-19 in Hospitalized Patients With Hypoxia

Phase: N/A Priority: Normal

NCT ID: NCT04363346 Org: User:

Start: 05/14/20 End: 02/18/21 Due: 02/18/22

Fitness and Lung Function Among Survivors of Heart Transplant, Leukemia and Infant BPD Through Exercise

Phase: N/A Priority: Normal

NCT ID: NCT05025774 Org: User:

Start: 03/14/25 End: 12/01/25 Due: 12/01/26

Reduced-Intensity Hematopoietic Stem Cell Transplant for High Risk Lysosomal and Peroxisomal Disorders

Phase: N/A Priority: Normal

NCT ID: NCT01626092 Org: User:

Start: 07/11/12 End: 11/30/13 Due: 11/30/14

T-Regulatory Cell Infusion Post Umbilical Cord Blood Transplant in Patients With Advanced Hematologic Cancer

Phase: N/A Priority: Normal

NCT ID: NCT00602693 Org: User:

Start: 07/23/07 End: 04/16/15 Due: 04/16/16

Sugars in Cigarettes

Phase: N/A Priority: Normal

NCT ID: NCT05308316 Org: User:

Start: 02/24/22 End: 05/31/26 Due: 05/31/27

Everolimus in Treating Women With Breast Cancer That Can Be Removed by Surgery

Phase: N/A Priority: Normal

NCT ID: NCT00855114 Org: User:

Start: 07/31/08 End: 06/30/09 Due: 06/30/10

Study of Cellutome System for Treatment of Individual Lesions in EB Pts

Phase: N/A Priority: Normal

NCT ID: NCT02670837 Org: User:

Start: 08/04/16 End: 04/03/24 Due: 04/03/25

Safety of Romiplostim (Nplate®) Following UCBT

Phase: N/A Priority: Normal

NCT ID: NCT02046291 Org: User:

Start: 04/10/15 End: 06/01/21 Due: 06/01/22

Auto Transplant for High Risk or Relapsed Solid or CNS Tumors

Phase: N/A Priority: Normal

NCT ID: NCT01505569 Org: User:

Start: 10/20/11 End: 02/01/24 Due: 02/01/25

Bone Marrow Transplantation in Treating Patients With Leukemia

Phase: N/A Priority: Normal

NCT ID: NCT00006451 Org: User:

Start: 04/30/96 End: 11/30/00 Due: 11/30/01

CD3/CD19 Depleted or CD3 Depleted/CD56 Selected Haploid Donor Natural Killer Cell Treatment in Older AML in First Complete Remission

Phase: N/A Priority: Normal

NCT ID: NCT01639456 Org: User:

Start: 10/31/13 End: 01/31/17 Due: 01/31/18

Stem Cell Transplant for Inborn Errors of Metabolism

Phase: N/A Priority: Normal

NCT ID: NCT00176904 Org: User:

Start: 01/31/95 End: 06/30/10 Due: 06/30/11

Chemotherapy, Total-Body Irradiation, Donor Natural Killer Cell Infusion, Aldesleukin, and UCB Transplant in Treating Patients With Relapsed or Refractory AML

Phase: N/A Priority: Normal

NCT ID: NCT00871689 Org: User:

Start: 01/31/09 End: 10/31/11 Due: 10/31/12

Clinical Trial of Trametes Versicolor in Women With Breast Cancer

Phase: N/A Priority: Normal

NCT ID: NCT00680667 Org: User:

Start: 04/30/07 End: 04/30/11 Due: 04/30/12

Rural Smoking Cessation

Phase: N/A Priority: Normal

NCT ID: NCT06584929 Org: User:

Start: 09/01/25 End: 08/31/29 Due: 08/31/30

MT2023-20: Hematopoietic Cell Transplant With Reduced Intensity Conditioning and Post-transplant Cyclophosphamide for Severe Aplastic Anemia and Other Forms of Acquired Bone Marrow Failure.

Phase: N/A Priority: Normal

NCT ID: NCT06412497 Org: User:

Start: 06/05/24 End: 05/01/36 Due: 05/01/37

American Indian Smokefree Native RCT

Phase: N/A Priority: Normal

NCT ID: NCT06544811 Org: User:

Start: 04/14/25 End: 10/01/29 Due: 10/01/30

CMV-MVA Triplex Vac.Enhance Adap. NK Cell Recon. After Auto HSCT in pt Lymphoid Malig

Phase: N/A Priority: Normal

NCT ID: NCT03383055 Org: User:

Start: 11/16/18 End: 07/10/21 Due: 07/10/22

Study of PAT in Patients With Solid Tumor Cancers

Phase: N/A Priority: Normal

NCT ID: NCT05338658 Org: User:

Start: 05/19/23 End: 01/31/27 Due: 01/31/28

Topotecan, Cisplatin, and Radiation Therapy in Treating Patients With Advanced Cervical Cancer

Phase: N/A Priority: Normal

NCT ID: NCT00287911 Org: User:

Start: 02/28/05 End: 12/31/09 Due: 12/31/10

Carboplatin, Docetaxel, and Radiation Therapy in Treating Patients With Stage III/IV, or Recurrent Endometrial Cancer

Phase: N/A Priority: Normal

NCT ID: NCT00258362 Org: User:

Start: 07/31/05 End: 12/31/09 Due: 12/31/10

Study of Immune Response Modifier in the Treatment of Breast, Ovarian, Endometrial and Cervical Cancers

Phase: N/A Priority: Normal

NCT ID: NCT00319748 Org: User:

Start: 04/30/06 End: 12/31/08 Due: 12/31/09

Title	NCT ID	Organization	User	Status	Start Date	End Date	Reporting Due Date	Last Checked	User Role	Org Created
Donor Umbilical Cord Blood Natural Killer Cells, Aldesleukin and Umbilical Cord Blood Transplant in Patients With Refractory Hematologic Cancers.	NCT00354172	Masonic Cancer Center, University of Minnesota	user2@example.com	None	2006-02-28	2008-08-31	2009-08-31	-	-	2025-07-14
MT2022-01: MSCs for ALD	NCT06030648	Masonic Cancer Center, University of Minnesota	user2@example.com	None	2023-08-28	2028-05-01	2029-05-01	-	-	2025-07-14
Probiotic Supplementation During Cytotoxic Chemotherapy for Solid Tumor Malignancies	NCT06772090	Masonic Cancer Center, University of Minnesota	user2@example.com	None	2025-12-25	2027-12-31	2028-12-31	-	-	2025-07-14
Study of FT516 for the Treatment of COVID-19 in Hospitalized Patients With Hypoxia	NCT04363346	Masonic Cancer Center, University of Minnesota	user2@example.com	None	2020-05-14	2021-02-18	2022-02-18	-	-	2025-07-14
Fitness and Lung Function Among Survivors of Heart Transplant, Leukemia and Infant BPD Through Exercise	NCT05025774	Masonic Cancer Center, University of Minnesota	user2@example.com	None	2025-03-14	2025-12-01	2026-12-01	-	-	2025-07-14
Reduced-Intensity Hematopoietic Stem Cell Transplant for High Risk Lysosomal and Peroxisomal Disorders	NCT01626092	Masonic Cancer Center, University of Minnesota	user2@example.com	None	2012-07-11	2013-11-30	2014-11-30	-	-	2025-07-14
T-Regulatory Cell Infusion Post Umbilical Cord Blood Transplant in Patients With Advanced Hematologic Cancer	NCT00602693	Masonic Cancer Center, University of Minnesota	user2@example.com	None	2007-07-23	2015-04-16	2016-04-16	-	-	2025-07-14
Sugars in Cigarettes	NCT05308316	Masonic Cancer Center, University of Minnesota	user2@example.com	None	2022-02-24	2026-05-31	2027-05-31	-	-	2025-07-14
Everolimus in Treating Women With Breast Cancer That Can Be Removed by Surgery	NCT00855114	Masonic Cancer Center, University of Minnesota	user2@example.com	None	2008-07-31	2009-06-30	2010-06-30	-	-	2025-07-14
Study of Cellutome System for Treatment of Individual Lesions in EB Pts	NCT02670837	Masonic Cancer Center, University of Minnesota	user2@example.com	None	2016-08-04	2024-04-03	2025-04-03	-	-	2025-07-14
Safety of Romiplostim (Nplate®) Following UCBT	NCT02046291	Masonic Cancer Center, University of Minnesota	user2@example.com	None	2015-04-10	2021-06-01	2022-06-01	-	-	2025-07-14
Auto Transplant for High Risk or Relapsed Solid or CNS Tumors	NCT01505569	Masonic Cancer Center, University of Minnesota	user2@example.com	None	2011-10-20	2024-02-01	2025-02-01	-	-	2025-07-14
Bone Marrow Transplantation in Treating Patients With Leukemia	NCT00006451	Masonic Cancer Center, University of Minnesota	user2@example.com	None	1996-04-30	2000-11-30	2001-11-30	-	-	2025-07-14
CD3/CD19 Depleted or CD3 Depleted/CD56 Selected Haploid Donor Natural Killer Cell Treatment in Older AML in First Complete Remission	NCT01639456	Masonic Cancer Center, University of Minnesota	user2@example.com	None	2013-10-31	2017-01-31	2018-01-31	-	-	2025-07-14
Stem Cell Transplant for Inborn Errors of Metabolism	NCT00176904	Masonic Cancer Center, University of Minnesota	user2@example.com	None	1995-01-31	2010-06-30	2011-06-30	-	-	2025-07-14
Chemotherapy, Total-Body Irradiation, Donor Natural Killer Cell Infusion, Aldesleukin, and UCB Transplant in Treating Patients With Relapsed or Refractory AML	NCT00871689	Masonic Cancer Center, University of Minnesota	user2@example.com	None	2009-01-31	2011-10-31	2012-10-31	-	-	2025-07-14
Clinical Trial of Trametes Versicolor in Women With Breast Cancer	NCT00680667	Masonic Cancer Center, University of Minnesota	user2@example.com	None	2007-04-30	2011-04-30	2012-04-30	-	-	2025-07-14
Rural Smoking Cessation	NCT06584929	Masonic Cancer Center, University of Minnesota	user2@example.com	None	2025-09-01	2029-08-31	2030-08-31	-	-	2025-07-14
MT2023-20: Hematopoietic Cell Transplant With Reduced Intensity Conditioning and Post-transplant Cyclophosphamide for Severe Aplastic Anemia and Other Forms of Acquired Bone Marrow Failure.	NCT06412497	Masonic Cancer Center, University of Minnesota	user2@example.com	None	2024-06-05	2036-05-01	2037-05-01	-	-	2025-07-14
American Indian Smokefree Native RCT	NCT06544811	Masonic Cancer Center, University of Minnesota	user2@example.com	None	2025-04-14	2029-10-01	2030-10-01	-	-	2025-07-14
CMV-MVA Triplex Vac.Enhance Adap. NK Cell Recon. After Auto HSCT in pt Lymphoid Malig	NCT03383055	Masonic Cancer Center, University of Minnesota	user2@example.com	None	2018-11-16	2021-07-10	2022-07-10	-	-	2025-07-14
Study of PAT in Patients With Solid Tumor Cancers	NCT05338658	Masonic Cancer Center, University of Minnesota	user2@example.com	None	2023-05-19	2027-01-31	2028-01-31	-	-	2025-07-14
Topotecan, Cisplatin, and Radiation Therapy in Treating Patients With Advanced Cervical Cancer	NCT00287911	Masonic Cancer Center, University of Minnesota	user2@example.com	None	2005-02-28	2009-12-31	2010-12-31	-	-	2025-07-14
Carboplatin, Docetaxel, and Radiation Therapy in Treating Patients With Stage III/IV, or Recurrent Endometrial Cancer	NCT00258362	Masonic Cancer Center, University of Minnesota	user2@example.com	None	2005-07-31	2009-12-31	2010-12-31	-	-	2025-07-14
Study of Immune Response Modifier in the Treatment of Breast, Ovarian, Endometrial and Cervical Cancers	NCT00319748	Masonic Cancer Center, University of Minnesota	user2@example.com	None	2006-04-30	2008-12-31	2009-12-31	-	-	2025-07-14

Compliance Rate

My Organizations' Clinical Trials

Appearance